August 30, 2016
(The Wall Street Journal) – In two days of hearings next month, the U.S. Food and Drug Administration will consider if clinics offering stem-cell treatments should be more closely regulated. Stem-cell treatments aren’t approved by the FDA and not long ago, Americans had to travel to Mexico, China or elsewhere to receive them. Now, with the regulatory environment murky, clinics offering them are spreading rapidly across the U.S. A recent report in the journal Cell Stem Cell counted 570 clinics advertising stem-cell therapies directly to consumers. Many claim to treat a long list of disorders, from arthritis to Alzheimer’s disease, even though the stem-cell treatment for many of the conditions hasn’t yet been tested on humans. Treatment typically costs thousands of dollars.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.